Neovacs S.A. (ALNEV.PA)
EUR 1.11
(-11.15%)
EUR 1.11
(-11.15%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -6.9 Million EUR | -7.44% |
| 2022 | -6.42 Million EUR | 17.99% |
| 2021 | -7.83 Million EUR | -124.44% |
| 2020 | -3.49 Million EUR | 57.76% |
| 2019 | -8.26 Million EUR | 36.78% |
| 2018 | -13.08 Million EUR | 31.36% |
| 2017 | -19.05 Million EUR | -10.4% |
| 2016 | -17.26 Million EUR | -53.04% |
| 2015 | -11.27 Million EUR | -16.84% |
| 2014 | -9.65 Million EUR | -22.23% |
| 2013 | -7.89 Million EUR | 4.14% |
| 2012 | -8.23 Million EUR | 19.26% |
| 2011 | -10.2 Million EUR | -1.64% |
| 2010 | -10.03 Million EUR | -19.84% |
| 2009 | -8.37 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.7 Million EUR | 0.0% |
| 2023 Q2 | -3.67 Million EUR | 0.0% |
| 2023 FY | -6.9 Million EUR | -7.44% |
| 2023 Q4 | -3.22 Million EUR | 0.0% |
| 2022 Q2 | -3.63 Million EUR | 0.0% |
| 2022 Q4 | -2.8 Million EUR | 0.0% |
| 2022 FY | -6.42 Million EUR | 17.99% |
| 2021 FY | -7.83 Million EUR | -124.44% |
| 2021 Q2 | -3.41 Million EUR | 0.0% |
| 2021 Q4 | -4.4 Million EUR | 0.0% |
| 2020 Q2 | -1.83 Million EUR | 0.0% |
| 2020 Q4 | -1.66 Million EUR | 0.0% |
| 2020 FY | -3.49 Million EUR | 57.76% |
| 2019 Q2 | -4.7 Million EUR | 0.0% |
| 2019 Q4 | -3.56 Million EUR | 0.0% |
| 2019 FY | -8.26 Million EUR | 36.78% |
| 2018 FY | -13.08 Million EUR | 31.36% |
| 2018 Q4 | -6.45 Million EUR | 0.0% |
| 2018 Q2 | -6.62 Million EUR | 0.0% |
| 2017 Q2 | -10.69 Million EUR | 0.0% |
| 2017 FY | -19.05 Million EUR | -10.4% |
| 2017 Q4 | -8.35 Million EUR | 0.0% |
| 2016 Q2 | -7.86 Million EUR | 0.0% |
| 2016 FY | -17.26 Million EUR | -53.04% |
| 2016 Q4 | -9.39 Million EUR | 0.0% |
| 2015 FY | -11.27 Million EUR | -16.84% |
| 2015 Q4 | -5.65 Million EUR | 0.0% |
| 2015 Q2 | -5.62 Million EUR | 0.0% |
| 2014 Q2 | -4.51 Million EUR | 0.0% |
| 2014 Q4 | -5.13 Million EUR | 0.0% |
| 2014 FY | -9.65 Million EUR | -22.23% |
| 2013 Q2 | -3.64 Million EUR | -81.91% |
| 2013 Q1 | -2 Million EUR | 0.0% |
| 2013 FY | -7.89 Million EUR | 4.14% |
| 2013 Q4 | -4.25 Million EUR | -112.11% |
| 2013 Q3 | -2 Million EUR | 45.03% |
| 2012 Q1 | -2.04 Million EUR | 0.0% |
| 2012 Q4 | -2 Million EUR | 1.94% |
| 2012 Q3 | -2.04 Million EUR | 0.0% |
| 2012 FY | -8.23 Million EUR | 19.26% |
| 2012 Q2 | -2.04 Million EUR | 0.0% |
| 2011 Q2 | -1.55 Million EUR | 0.0% |
| 2011 Q3 | -1.55 Million EUR | 0.0% |
| 2011 Q4 | -2.04 Million EUR | -31.34% |
| 2011 FY | -10.2 Million EUR | -1.64% |
| 2011 Q1 | -1.55 Million EUR | 0.0% |
| 2010 Q2 | -2.57 Million EUR | 0.0% |
| 2010 Q3 | -2.57 Million EUR | 0.0% |
| 2010 Q4 | -1.55 Million EUR | 39.56% |
| 2010 Q1 | -2.57 Million EUR | 0.0% |
| 2010 FY | -10.03 Million EUR | -19.84% |
| 2009 Q3 | -2.1 Million EUR | 0.0% |
| 2009 Q1 | -2.1 Million EUR | 0.0% |
| 2009 FY | -8.37 Million EUR | 0.0% |
| 2009 Q2 | -2.1 Million EUR | 0.0% |
| 2009 Q4 | -2.57 Million EUR | -22.27% |
| 2008 Q4 | -2.1 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -102.449% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 94.577% |
| Adocia SA | -17.62 Million EUR | 60.802% |
| Aelis Farma SA | -6.46 Million EUR | -6.911% |
| Biophytis S.A. | -14.33 Million EUR | 51.807% |
| Advicenne S.A. | -6.45 Million EUR | -6.978% |
| genOway Société anonyme | 2.06 Million EUR | 434.458% |
| IntegraGen SA | -183.77 Thousand EUR | -3658.801% |
| Medesis Pharma S.A. | -4.22 Million EUR | -63.324% |
| NFL Biosciences SA | -4.43 Million EUR | -55.912% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -787.589% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -120.178% |
| Sensorion SA | -22.31 Million EUR | 69.039% |
| Theranexus Société Anonyme | -7.64 Million EUR | 9.631% |
| TME Pharma N.V. | -5.62 Million EUR | -22.823% |
| Valbiotis SA | -7.16 Million EUR | 3.526% |
| TheraVet SA | -2.17 Million EUR | -217.573% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 65.953% |
| argenx SE | -417.15 Million EUR | 98.344% |
| BioSenic S.A. | -7.04 Million EUR | 1.881% |
| Celyad Oncology SA | -8.45 Million EUR | 18.322% |
| DBV Technologies S.A. | -85.24 Million EUR | 91.897% |
| Galapagos NV | -88.26 Million EUR | 92.174% |
| Genfit S.A. | -26.58 Million EUR | 74.012% |
| GeNeuro SA | -14.35 Million EUR | 51.888% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 56.809% |
| Innate Pharma S.A. | -12.66 Million EUR | 45.477% |
| Inventiva S.A. | -102.7 Million EUR | 93.275% |
| MaaT Pharma SA | -19.94 Million EUR | 65.364% |
| MedinCell S.A. | -20.97 Million EUR | 67.071% |
| Nanobiotix S.A. | -26.77 Million EUR | 74.205% |
| Onward Medical N.V. | -35.46 Million EUR | 80.522% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -51.841% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 69.949% |
| Oxurion NV | -12.11 Million EUR | 42.96% |
| Pharming Group N.V. | -4.87 Million EUR | -41.561% |
| Poxel S.A. | -28.76 Million EUR | 75.985% |
| GenSight Biologics S.A. | -29.69 Million EUR | 76.739% |
| Transgene SA | -30.01 Million EUR | 76.984% |
| Financière de Tubize SA | -2.14 Million EUR | -222.184% |
| UCB SA | 604 Million EUR | 101.144% |
| Valneva SE | -82.08 Million EUR | 91.585% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 76.046% |